$1.21
+0.01 (+0.83%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TLPH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 16 with posted results
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC) · FINRA short interest 3.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Nafamostat Efficacy in Phase 3 Registrational CRRT StudyNCT06150742mean post-filter activated clotting time (ACT)Randomized · Quadruple-masked · Treatment | Not applicable | Recruiting | Device: Niyad (nafamostat mesylate), Placebo (0.9% NaCl) | Acute Kidney Injury | 70 | Dec 2025 | 2025-10-15 |
| Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcgNCT02662764results2018-08-08Percentage of Patients Who Experienced at Least One System-generated Error Based on the Controller Data While Using the Zalviso SystemOpen-label · TreatmentStatistical Analysis Plan ↗ · Informed Consent Form ↗ · Study Protocol ↗ | Phase 3 | Completed | Drug: Zalviso™ 15 mcg | Moderate-to-severe Acute Pain | 320 | 2017-04-14actual | 2018-08-08 |
| Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute PainNCT02447848results2017-10-19Time-weighted Summed Pain Intensity Difference (SPID) Over the 1-hour (SPID1).Open-label · Treatment | Phase 3 | Completed | Drug: sufentanil sublingual 30 mcg tablet | Moderate-to-severe Acute Pain | 76 | Jun 2016actual | 2017-10-19 |
| A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative PainNCT02662556results2017-03-15Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12).Open-label · Treatment | Phase 3 | Completed | Drug: sufentanil sublingual tablet 30 mcg | Acute Moderate-to-severe Pain | 140 | Jun 2016actual | 2017-03-15 |
| A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal SurgeryNCT02356588results2017-02-13Time-weighted Summed Pain Intensity Difference (SPID) Over the 12-hour Study Period (SPID12).Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Sufentanil Tablet 30 mcg, Placebo Tablet | Post-Operative Pain | 161 | Jun 2015actual | 2017-02-13 |
| Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy SubjectsNCT02082236Area Under the CurveRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Treatment Arm A: Sufenta®, Treatment B: Sufentanil SSM 30 mcg, Treatment C: SSM 15 mcg, Treatment D: SSM 30 mcg | Healthy | 40 | May 2014actual | 2018-07-17 |
| Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement SurgeryNCT01660763results2014-02-03Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID48).Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System | Post Operative Pain | 419 | Apr 2013actual | 2015-10-20 |
| Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following BunionectomyNCT01710345results2015-01-26SPID-12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Sufentanil NanoTab 20 mcg, Sufentanil NanoTab 30 mcg, Placebo NanoTab | Acute Pain | 101 | Feb 2013actual | 2015-01-26 |
| Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTabNCT01761565results2015-02-11CmaxNon-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Single dose of SUF NT 15 mcg, 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes | Plasma Concentrations | 40 | Feb 2013actual | 2015-10-01 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal SurgeryNCT01539642results2014-02-03Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID-48).Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Sufentanil NanoTab PCA System/15 mcg, Placebo Sufentanil NanoTab PCA System | Post-Operative Pain | 172 | Jan 2013actual | 2015-10-20 |
| A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative PainNCT01539538results2014-03-27Patient Global SatisfactionRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA | Post-Operative Pain | 357 | Dec 2012actual | 2015-10-01 |
| Effect of Ketoconazole on Sufentanil NanoTab PharmacokineticsNCT01721070results2014-03-26AUC (0-inf)Non-randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg | Pharmacokinetics | 19 | Dec 2012actual | 2016-11-04 |
| Effect of Delivery Route on PK of Sufentanil NanoTabNCT01639729results2014-05-21AUC (0 - Inf)Randomized · Open-label · Basic science | Phase 1 | Completed | Drug: Treatment A: Sufentanil IV, Treatment B: Sufentanil NanoTab Sublingual, Treatment C: Sufentanil NanoTab Buccal, Treatment D: Sufentanil NanoTab Oral | Pharmacokinetics | 25 | Jul 2012actual | 2015-10-01 |
| A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough PainNCT00833040results2015-01-01Time-weighted SPID30Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™ | Cancer, Pain | 34 | Mar 2010actual | 2015-01-01 |
| A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction ProcedureNCT00894699results2014-06-25Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03), Placebo NanoTab™ | Sedation, Anxiety, Pain | 40 | Sep 2009actual | 2014-06-25 |
| An Open-Label Functionality, Safety and Efficacy Study in Patients Undergoing Elective Unilateral Knee ReplacementNCT00859313results2012-02-27Percent of Patients Without Device FailureOpen-label · Treatment | Phase 2 | Completed | Drug: Sufentanil NanoTab PCA System/15 mcg | Pain, Postoperative | 30 | Aug 2009actual | 2012-03-01 |
| A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal SurgeryNCT00718081results2015-01-22SPID-12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Oral sufentanil, Placebo | Major Upper or Lower Abdominal Surgery | 88 | Mar 2009actual | 2015-01-22 |
| A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Elective Unilateral Total Knee ReplacementNCT00612534results2014-02-17SPID-12Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Sufentanil NanoTab, Placebo NanoTab, Sufentanil NanoTab, Sufentanil NanoTab | Post Operative Pain | 94 | Oct 2008actual | 2014-02-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19